Cargando…

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy

Bortezomib (bort) is an effective therapeutic agent for patients with multiple myeloma (MM); however, most patients develop drug resistance. Autophagy, a highly conserved process that recycles cytosol or entire organelles via lysosomal activity, is essential for the survival, homeostasis, and drug r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jing, Cao, Wen, Huang, Xi, Chen, Qingxiao, Ye, Shuting, Qu, Jianwei, Liu, Yang, Guo, Xing, Yao, Shunnan, Zhang, Enfan, He, Jingsong, Li, Anqi, Yang, Li, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561007/ https://www.ncbi.nlm.nih.gov/pubmed/37083684 http://dx.doi.org/10.1182/bloodadvances.2022008241

Ejemplares similares

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2022)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma
por: Edwards, Camille V., et al.
Publicado: (2022)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
por: Barnell, Erica K., et al.
Publicado: (2022)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Linked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma
por: Peña-Pérez, Lucía, et al.
Publicado: (2022)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology
por: Hoelzinger, Dominique B., et al.
Publicado: (2022)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Uptake of long-chain fatty acids from the bone marrow suppresses CD8(+) T-cell metabolism and function in multiple myeloma
por: Gudgeon, Nancy, et al.
Publicado: (2023)

Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma
por: Brownlie, Rebecca J., et al.
Publicado: (2023)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21
por: Zaaboub, Rim, et al.
Publicado: (2022)

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A-rearranged leukemia
por: Chen, Changya, et al.
Publicado: (2022)

Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion
por: Zhang, Ming, et al.
Publicado: (2022)

Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM
por: Wang, Jun, et al.
Publicado: (2022)

YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia
por: Li, Huan, et al.
Publicado: (2023)

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
por: Wu, Chi-Heng, et al.
Publicado: (2022)

Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
por: Ren, Weicheng, et al.
Publicado: (2022)

Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia
por: Li, Zhenhua, et al.
Publicado: (2021)

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia
por: Jiang, Chuang, et al.
Publicado: (2022)

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
por: Brown-Burke, Fiona, et al.
Publicado: (2023)

USP1 promotes the aerobic glycolysis and progression of T-cell acute lymphoblastic leukemia via PLK1/LDHA axis
por: Liu, Shuguang, et al.
Publicado: (2023)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide–coated nanoparticles
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
por: Bridges, Cory Seth, et al.
Publicado: (2022)

Structural variation cooperates with permissive chromatin to control enhancer hijacking–mediated oncogenic transcription
por: Botten, Giovanni A., et al.
Publicado: (2023)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells
por: Yang, Scarlett Y., et al.
Publicado: (2022)

Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia
por: Mittelman, Steven D., et al.
Publicado: (2021)

Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia
por: Ferguson, Daniel C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6qq5307dqfjf4rns8p25lrl3ht